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ABSTRACT
Preoperative identification of individuals at low risk of lymph node metastasis 
is key to the proper management of endometrial cancer. This study evaluated the 
role of preoperative assessment based on magnetic resonance imaging (MRI) and 
histological analysis in identifying a group having a low risk of lymph node metastasis. 
Data of 529 patients with endometrial cancer were obtained from a prospective 
multicenter database, between January 2012 and December 2014. Clinical staging, 
based on MRI and histological analysis, was compared with final pathology results 
after the surgical staging procedure. The preoperative low-risk criteria, based on 
current guidelines from Korea, France, and Canada, and criteria used for fertility-
sparing therapies, were applied to our multicenter cohort and the accuracy of each set 
of criteria for identifying group at low risk of lymph node metastasis was evaluated. 
When considering grades or MR stages separately, the overall agreement between 
preoperative and postoperative findings was poor (Kappa 0.45 for grades; 0.41 for 
stages). However, when combining these two parameters, the low-risk group, as 
defined by any of the guidelines, had an acceptable rate of lymph node metastasis 
(below 3%). The French guidelines identified 249 patients (47.1%) as being in the 
low-risk group. Criteria used to define fertility-sparing therapy candidates identified 
48 patients (9.1%) among the study population, only one of whom had extra-uterine 
disease. This study shows that the current guidelines, using preoperative assessment 
based on MRI and histological analysis, can identify low-risk patients, who may be 
candidates for omitting lymphadenectomy.
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INTRODUCTION
In 1988, the International Federation of Obstetrics 
and Gynecology (FIGO) recommended surgical staging 
for endometrial cancer patients [1]. Although two 
randomized controlled studies failed to show a survival 
benefit for performing lymphadenectomy over not 
performing this procedure, the value of lymphadenectomy 
for the treatment of endometrial cancer remains 
controversial [2, 3]. The current guidelines recommend 
that lymphadenectomy should be performed for selected 
patients, but the need for lymphadenectomy could be 
avoided in a low-risk group [4–8]. Therefore, preoperative 
and intraoperative assessment is key to the proper surgical 
management of this disease subset.
Recently, the Korean Gynecologic Oncology Group 
(KGOG) proposed a preoperative prediction model for 
lymph node metastasis, using serum CA-125 levels 
and MRI parameters [9]. In addition, the accuracy and 
reliability of this model for identifying a low-risk group 
has been confirmed in a prospective cohort [10]. However, 
approximately 60% of KGOG members prefer to use 
routine lymphadenectomy, even in patients satisfying the 
KGOG-2015 low-risk criteria [11], and some decide on 
lymphadenectomy based on preoperative imaging and the 
grade of the tumor, as determined through biopsies, prior 
to surgery.
Each guideline proposes specific criteria for the low-
risk group, based on various combinations of preoperative 
histology and MRI parameters. In addition, decisions 
about fertility-sparing therapies are solely dependent on 
clinical staging, based on preoperative assessment [4, 
12]. However, the actual risk of extra-uterine disease in 
patients that satisfy the above-mentioned criteria has not 
yet been determined in diverse clinical settings.
The aim of this study was to evaluate the rate of 
upgrading and upstaging between preoperative assessment 
and final surgical pathology in a multicenter prospective 
cohort of patients with endometrial cancer who had 
undergone surgical staging (KGOG-2015) [10]. In 
addition, we evaluated the performance of preoperative 
assessment based on current guidelines and fertility-
sparing therapies for identifying a group at low risk of 
endometrial cancer.
RESULTS
Comparison of clinical and surgical staging
A total of 529 patients were included in the analysis 
(Table 1). The overall agreement between preoperative and 
postoperative grading was poor, according to the Kappa 
statistics (0.45). Among the 244 cases with preoperative 
grade 1 disease, the preoperative and postoperative 
pathology were in agreement in 190 (77.9%) patients, 
but the final pathology grade was advanced to grade 2 in 
41 (16.8%) and to grade 3 in 7 (2.9%) of these patients 
(Table 2). Among the 127 cases with preoperative grade 
2 disease, 72 (56.7%) showed correlation with the final 
pathology report, whereas 17 (13.4%) were upgraded to 
grade 3.
The performance of preoperative MRI in predicting 
the final stage is reported in Table 2. Concordance between 
the preoperative and postoperative MR stage was 67.9%, 
with a kappa of 0.41. Of the 354 patients with preoperative 
MRI stage IA, 49 (13.8%) patients were upstaged; 
12 (3.4%) patients with lymph node metastasis were 
categorized as having stage IIIC, and 3 (0.9%) patients 
with extra-uterine metastasis as having stage IV disease.
Performance of preoperative low-risk criteria by 
current guidelines
The performance of the KSGO, SOGC, INCa low-
risk criteria, and fertility-sparing therapies was assessed by 
applying them to all 529 patients (Table 3).
The KSGO guidelines identified 178 patients as 
being in the low-risk group for lymph node metastasis. 
Of these 178 patients, only 3 patients (1.7%) actually had 
lymph node metastasis. For the diagnosis of lymph node 
metastasis, the KSGO low-risk criteria had an AUC of 
0.65 (95% CI: 0.62-0.69). The SOGC guidelines identified 
204 patients with preoperative grade 1 and presumed stage 
I disease. In this low-risk group, only 4 patients (2.0%) 
had lymph node metastasis. For the diagnosis of lymph 
node metastasis, the SOGC low-risk criteria had an 
AUC of 0.67 (95% CI: 0.63-0.71). The INCa guidelines 
identified 249 patients as being in the low-risk group 
for lymph node metastasis. Among these patients in the 
low-risk group, lymph node metastasis was found only 
in 6 patients (2.4%). For the diagnosis of lymph node 
metastasis, the INCa criteria had an AUC of 0.70 (95% 
CI: 0.65-0.75).
For fertility-sparing options, the NCCN suggests the 
following low-risk criteria: MR stage IA, endometrioid, 
grade 1, and young women desiring fertility preservation. 
In our database, 48 patients were candidates for fertility-
sparing therapies. Of the 48 patients, only one patient 
(2.1%), who had lymph node metastasis, had extra-uterine 
disease. These criteria had an AUC of 0.54 (95% CI: 0.52-
0.56) for the diagnosis of lymph node metastasis. When 
expanding fertility-sparing therapies to KGOG-2020, 99 
patients were identified. Of these, two patients (2.0%) 
already had lymph node metastasis.
We used a Venn diagram to show the low-risk group 
for lymph node metastasis and how they satisfied the 
various guidelines (Figure 1). In our cohort, candidate 
fertility-sparing therapies were the most conservative for 
identifying a group at low risk for lymph node metastasis, 
and patients designated as being at low risk, based on 
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fertility-sparing therapy criteria, also completely satisfied 
KSGO criteria. By using SOGC and INCa guidelines, 
we would have identified more low-risk group patients 
than by using the KSGO guidelines, without a significant 
increase in the false-negative rate.
DISCUSSION
In this study, we evaluated the role of preoperative 
assessment based on MRI and histological analysis in 
identifying a group at low-risk of endometrial cancer. 
When the grades or MR stages are considered separately, 
the overall agreement between preoperative and 
postoperative findings was poor. However, a combined 
analysis of preoperative parameters is highly sensitive in 
predicting extra-uterine disease, in particular lymph node 
metastasis, and may result in the accurate identification of 
patients with endometrial cancer who are at low risk for 
lymph node metastasis.
The first objective of this study was to correlate the 
grade and stage based on preoperative assessment with that 
of the final pathology. Our study results correlated with 
Table 1: Characteristics of study population
 No. (%)
Age, median (range), y 53 (28-81)
Menopause 348 (65.8)
Route of surgery  
 Laparotomy 102 (19.3)
 Laparoscopy/robotic 427 (80.7)
Method of biopsy  
 Dilatation and curettage 427 (80.7)
 Other 102 (19.3)
Preoperative serum CA-125, median (range), U/mL 17.7 (1.0-1138.3)
Histologic type  
 Endometrioid 465 (87.9)
 Nonendometrioid 64 (12.1)
Tumor grade  
 I/II 416 (78.6)
 III or not determined 113 (21.4)
Myometrial invasion  
 <1/2 406 (76.7)
  ≥1/2 123 (23.3)
Tumor size  
 <2cm 229 (43.3)
  ≥2cm 300 (56.7)
Lymphovascular space invasion  
 No 431 (81.5)
 Yes 98 (18.5)
Para-aortic lymph node dissection  
 No 305 (57.7)
 Yes 224 (42.3)
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those of previous studies [13–15]. Body et al. showed that 
preoperative assessment had a 90% negative-predictive 
value for the diagnosis of grade 3 tumors [15]. Batista et 
al. suggested that preoperative endometrial sampling was 
found to be a modest overall predictor of postoperative 
histological grading [14]. They showed that 15.2% 
of patients with preoperative grade 1 diagnosis were 
upgraded after hysterectomy. Baek et al. found extensive 
upgrading (16.2%), based on the final pathology report 
from hysterectomy specimens in cases of preoperative 
grade 1 disease [13]. In line with previous reports, 
the overall level of agreement between preoperative 
and postoperative grading was also disappointing. We 
showed that upgrading occurred in 19.7% of patients 
with preoperative grade 1 disease. In addition, previous 
studies have demonstrated the diagnostic performance 
of MRI for evaluating myometrial invasion and lymph 
node metastasis [15–17]. Some studies have specifically 
evaluated the performance of MRI for FIGO staging and 
have shown an underestimation rate of approximately 
20% [15]. This finding is similar to that of our study; thus, 
preoperative evaluation based on MRI is incomplete.
Current guidelines recommend a more selective 
and tailored lymphadenectomy rather than routine 
lymphadenectomy in the management of endometrial 
cancer. The NCCN guidelines suggest that the extent of 
surgical staging can be determined based on preoperative 
and intraoperative findings [4]. Deciding whether to 
perform lymphadenectomy based on preoperative findings 
has some advantages. As there has been increasing 
demand for surgeons to provide the necessary information 
prior to treatment, this is suitable for preoperative decision 
counseling. However, there is currently no consensus 
definition of a low-risk group for lymph node metastasis. 
Several guidelines have suggested that, for patients 
meeting the low-risk criteria, lymphadenectomy could 
be omitted safely, based on preoperative parameters [5, 
7, 8]. Considering that few studies have validated the 
characteristics of low-risk criteria used in the current 
guidelines, our study has value in that it evaluated the 
performance of the preoperative criteria used in the 
current guidelines, and simultaneously compared them in 
an independent cohort.
We showed that the low-risk group as defined by 
any of the guidelines had an acceptable rate of lymph 
node metastasis, and a high negative-predictive value. 
This suggests that the decision to omit lymphadenectomy 
based on any of the guidelines could be justified. A 
previous study has shown treatment preferences for no 
lymphadenectomy over routine lymphadenectomy in 
Table 2: Correlation between preoperative assessment and final pathology
a) Grade
Postoperative 
 Preoperative
G1 G2 G3
G1 190 (77.9%) 36 (28.4%) 4 (6.8%)
G2 41 (16.8%) 72 (56.7%) 26 (26.3%)
G3 7 (2.9%) 17 (13.4%) 12 (12.1%)
N/A 6 (2.5%) 2 (1.6%) 24 (24.2%)
Upgraded patients (%) 19.7 13.4 N/A
b) Stage
Pathologic stage 
 Preoperative stage by magnetic resonance imaging
IA IB II IIIA IIIB IIIC IV
IA 305 (86.2%) 24 (35.8%) 5 (21.7%) 3 (100%) 0 (0%) 24 (34.3%) 5 (41.7%)
IB 22 (6.2%) 30 (44.8%) 4 (17.4%) 0 (0%) 0 (0%) 9 (12.9%) 3 (25.0%)
II 12 (3.4%) 5 (7.5%) 9 (39.1%) 0 (0%) 0 (0%) 3 (4.3%) 1 (8.3%)
IIIA 0 (0%) 3 (4.5%) 3 (13.0%) 0 (0%) 0 (0%) 2 (2.9%) 1 (8.3%)
IIIB 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.4%) 0 (0%)
IIIC 12 (3.4%) 5 (7.5%) 1 (4.4%) 0 (0%) 0 (0%) 23 (32.9%) 1 (8.3%)
IV 3 (0.9%) 0 1 (4.4%) 0 (0%) 0 (0%) 8 (11.4%) 1 (8.3%)
Upstaged patients (%) 13.8 19.4 21.7 0 0 11.4 0
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Table 3: Evaluation of low-risk criteria according to KSGO, SOGC, INCa, and fertility-sparing therapy candidates
  
Low risk group FSS candidates
KSGO (n=178) SOGC (n=204) INCa (n=249) NCCN (n=48) KGOG 2020 (n=99)
Pathologic stage      
 IA 166 (93.3%) 176 (86.3%) 225 (90.4%) 47 (97.9%) 94 (95.0%)
 IB 8 (4.5%) 21 (10.3%) 12 (4.8%) 0 (0%) 0 (0%)
 II 1 (0.6%) 1 (0.5%) 6 (2.4%) 0 (0%) 3 (3.0%)
 IIIA 0 (0%) 2 (1.0%) 0 (0%) 0 (0%) 0 (0%)
 IIIB 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 IIIC 3 (1.7%) 4 (2.0%) 6 (2.4%) 1 (2.1%) 2 (2.0%)
 IV 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
≥Stage II 4 (2.3%) 7 (3.4%) 12 (4.8%) 1 (2.1%) 5 (5.1%)
Lymph node 
metastasis 3 (1.7%) 4 (2.0%) 6 (2.4%) 1 (2.1%) 2 (2.0%)
AUC* (95% CI) 0.65 (0.62-0.69) 0.67 (0.63-0.71) 0.70 (0.65-0.75) 0.54 (0.52-0.56) 0.58 (0.55-0.61)
*For the diagnosis of lymph node metastasis.
FSS, fertility-sparing surgery; KSGO, Korean Society of Gynecologic Oncology; SOGC, Society of Obstetricians and 
Gynaecologists of Canada; INCa, French National Cancer Institute (INCa); NCCN, National Cancer Comprehensive 
Network; KGOG, Korean Gynecologic Oncology Group; AUC, area under the curve; CI, confidence interval.
Figure 1: Venn diagram for distribution of low-risk group according to various criteria. The area of circle is proportional 
to the number of low risk group per criteria. Lymph node metastasis is described by patient icon.
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early-stage endometrial cancer [18]. They showed that 
the majority of patients would accept a small amount of 
recurrence risk (within 3%) to reduce the incidence of 
lymphedema from routine lymphadenectomy. Under a 
selective lymphadenectomy strategy, patients who were 
unstaged based on false-negative results from low-risk 
group are likely to have a higher recurrence risk due to 
unidentified metastatic disease. In our study, the false-
negative rate from models did not exceed 3%.
In our cohort, fertility-sparing therapies identified 
the low-risk group very conservatively, while the 
Canadian and French guidelines identified more 
candidates for such therapies, omitting lymphadenectomy, 
with a low likelihood of lymph node metastasis. Our 
study demonstrates that the current guidelines may be 
considered safe for practice.
Decisions regarding fertility-sparing therapies 
are solely dependent on clinical staging based on a 
preoperative assessment. In Korea, approximately 11.5% 
of endometrial cancer patients were younger than 40 years, 
which is higher than the 4% of such patients in the US [19, 
20]. Candidates for fertility-sparing therapies are generally 
considered to be women younger than 40 years, with the 
disease limited to the endometrium, well-differentiated, 
endometrioid, with no extra-uterine disease, and who 
have a strong desire to preserve the uterus. We have shown 
that the risk of extra-uterine disease is low in this disease 
subset. In addition, there is little evidence that fertility-
sparing therapies could be considered for reproductive-
aged patients who have grade 2, stage IA endometrioid 
adenocarcinoma with myometrial invasion. Given the 
efforts to expand the number of candidates eligible for 
fertility-sparing therapies, KGOG-2020 is a single-arm 
phase II study evaluating the efficacy of fertility-sparing 
management in young women with stage I endometrial 
cancer with grade 2 or superficial myometrial invasion. 
In our study, when expanding fertility-sparing therapies 
in KGOG-2020, the rate of extra-uterine disease was low, 
and the criteria used had a high negative-predictive value 
for lymph node metastasis.
In conclusion, the criteria used in the current 
guidelines can identify a group with a low risk of lymph 
node metastasis. This study has useful implications 
for physicians counseling patients who desire to avoid 
lymphadenectomy. Our findings suggest that the vast 
majority of women could safely avoid lymphadenectomy, 
with its potential increased lymphedema risk.
MATERIALS AND METHODS
From January 2012 to December 2014, 537 patients 
with endometrial cancer were enrolled into a prospective, 
multicenter cohort study (KGOG-2015), involving 20 
hospitals in three countries, i.e., Korea, Japan, and China 
[10]. All participating patients had biopsy-confirmed 
endometrial cancer and underwent preoperative MRI and 
CA-125 before surgery. Comprehensive surgical staging, 
including systematic lymphadenectomy, was performed 
for all patients in this study. Patients were staged on 
the basis of final pathological findings according to the 
2009 FIGO classification. Nine patients were excluded 
due to inadequate imaging study (n = 1), no lymph 
node dissection (n = 4), and proven sarcoma (n = 3). All 
patients underwent MRI of the pelvis at either 1.5T or 3T 
scanners with a phased-array body coil. MR sequences of 
each institution varied because of our retrospective study 
design, but the common sequences in all institutions were 
precontrast T2-weighted images, precontrast T1-weighted 
images (T1W1), post-contrast T1W1 after a standard dose 
of gadolinium administration, and diffusion weighted 
image. There were no sequences with slice thickness 
larger than 7.5mm.
Data collection
After gaining approval from the Institutional Review 
Board of Yonsei University Hospital, the following data 
were collected for all patients: patient characteristics (age, 
body mass index [BMI], menopausal status), preoperative 
assessment (MRI finding, histological results, CA-125), 
information about surgery (type of procedure, approach, 
extent of surgery), postoperative pathological findings.
For preoperative MRI, the data for preoperative 
assessment (myometrial invasion depth, tumor size, 
suspicious lymph node metastasis, cervical, adnexa, 
and serosal involvement, vaginal involvement, extra-
uterine metastasis) were collected. For preoperative 
histology, tumor grade, histological subtypes, the methods 
used (dilatation & curettage, endometrial sampling, 
hysteroscopy) were recorded. In terms of postoperative 
pathological findings, histological subtypes, tumor grade, 
cytological results, lymphovascular space invasion, 
and FIGO stage 2009 were recorded. No central review 
was performed for preoperative MRI and pathologic 
examinations, and details of measurements have been 
described in a previous report [10].
Definition of a low-risk group
Three models based on preoperative assessment 
were identified from guidelines via a PubMed search. 
The Korean Society of Gynecologic Oncology (KSGO) 
defines the low-risk group for lymph node metastasis as 
preoperative grade 1, with endometrioid histology and 
superficial myometrial involvement [5, 12]. The Society 
of Obstetricians and Gynecologists of Canada (SOGC) 
defines low-risk disease as grade 1 adenocarcinoma on 
preoperative biopsy, and suggests that lymphadenectomy 
could be omitted in this low-risk group [7]. The French 
National Cancer Institute (INCa) classifies three risk 
groups, based on preoperative assessment, as follows: 
low risk—stage IA, grades 1 or 2, endometrioid type; 
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intermediate risk—stage IA, grade 3, and stage IB, grades 
1 or 2, endometrioid type; high risk—stage IB, grade 3, 
endometrioid type, and any stage with non-endometrioid 
type [8]. They do not recommend lymphadenectomy in the 
low-risk group.
In terms of fertility-sparing therapies, the current 
guidelines suggest that this option should be selectively 
used for young women who desire fertility preservation. 
The NCCN and KSGO guidelines recommend fertility-
sparing therapies in selected patients with biopsy-
proven grade 1, stage IA (limited to the endometrium on 
MRI) endometrioid adenocarcinoma [4, 12]. Decisions 
regarding fertility-sparing therapies are solely dependent 
on preoperative assessment. The KGOG-2020 is a single-
arm phase II trial evaluating the feasibility and safety 
of expanding fertility-sparing therapies to stage IA 
(superficially invading myometrium) and grade 2.
Statistical analysis
The results of the preoperative assessment were 
compared with the final pathological analysis of the 
surgical specimen. In terms of tumor grade, the agreement 
levels between the preoperative and postoperative 
pathological findings were analyzed using Kappa statistics 
with 95% confidence intervals. Descriptive analysis was 
performed to evaluate the rate of upstaging during surgical 
staging, as compared to preoperative MRI staging. In 
addition, we evaluated the performance of preoperative 
low-risk criteria, including those of the KSGO, SOGC, 
INCa, and fertility-sparing therapies. The area under the 
curve (AUC) was calculated for predicting lymph node 
metastasis. Analysis was performed using STATA 12.0 
(StatCorp, College Station, TX, USA). P < 0.05 was 
considered to be statistically significant and all P-values 
were two-sided. Patients with missing or unclear data for 
calculating the probability of lymph node metastasis were 
excluded when evaluating each criterion. No imputation 
method was applied.
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